Agomab

News

Three more biotechs price their Nasdaq IPOs

AgomAb, SpyGlass, and Veradermics have all set the terms for their IPOs this week, looking to raise somewhere between around $150m and $200m.

News

AgomAb and SpyGlass push the IPO button

Glimmers of a renewal of biotech IPO activity in 2026 have continued with the news that AgomAb and SpyGlass Pharma are sizing up investor interest.

News

Alpha-9's $175m third-round heads latest biotech financings

Radiopharma start-up Alpha-9 Oncology has closed a sizeable third investment round, heading a list of recent financings that also feature Axonis, Kivu Bio, SynOx, Agomab, and Blue Earth The

News

Agomab raises $100m for Crohn’s drug, and other financings

Agomab Therapeutics has closed a $100 million third-round financing, heading a list of recent funding rounds that also features AstronauTx, MinervaX, Precede Bio and Limma

Three more biotechs price their Nasdaq IPOs

AgomAb and SpyGlass push the IPO button

Alpha-9's $175m third-round heads latest biotech financings

Agomab raises $100m for Crohn’s drug, and other financings

Allogeneic cell therapy isn’t dead, with Brian Culley

How to meet your physicians where they are online

Agomab

Editor's Picks